Immune infiltration in pancreatic cancer (WP5285)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
Immune cell infiltration in pancreatic cancer. Various factors are secreted in the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) that can either stimulate or inhibit PDAC development. Alteration of PDAC development by immune cells can be direct and/or indirect. Used cell name abbreviations: MDSC = myeloid-derived suppressor cell, Treg = regulatory T cell, CAF = cancer associated fibroblast, PSC = pancreatic stellate cell, Th = CD4+ T helper cell.

Authors

Isabel Wassink , Martina Summer-Kutmon , Daniela Digles , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

CPTAC Diseases PancCanNet

Annotations

Cell Type Ontology

regulatory T cell neutrophil T-helper 1 cell fibroblast macrophage pancreatic stellate cell T-helper 17 cell T-helper 2 cell myeloid suppressor cell

Pathway Ontology

pancreatic cancer pathway immune response pathway disease pathway

Disease Ontology

pancreatic cancer

Participants
Query Drugst.One

Label Type Compact URI Comment
NO Metabolite chebi:16480
CO Metabolite chebi:17245
CXCL5 GeneProduct ensembl:ENSG00000163735
CCL28 GeneProduct ensembl:ENSG00000151882
CCL2 GeneProduct ensembl:ENSG00000108691
IL17F GeneProduct ensembl:ENSG00000112116
VEGFD GeneProduct ensembl:ENSG00000165197
TGFB3 GeneProduct ensembl:ENSG00000119699
CCL5 GeneProduct ensembl:ENSG00000271503
IL17D GeneProduct ensembl:ENSG00000172458
CXCL12 GeneProduct ensembl:ENSG00000107562
IL25 GeneProduct ensembl:ENSG00000166090
LGALS3 GeneProduct ensembl:ENSG00000131981
IL17C GeneProduct ensembl:ENSG00000124391
IL23A GeneProduct ensembl:ENSG00000110944
TGFB2 GeneProduct ensembl:ENSG00000092969
IL1B GeneProduct ensembl:ENSG00000125538
IL10 GeneProduct ensembl:ENSG00000136634
CSF2 GeneProduct ensembl:ENSG00000164400
REG4 GeneProduct ensembl:ENSG00000134193
IL17B GeneProduct ensembl:ENSG00000127743
VEGFB GeneProduct ensembl:ENSG00000173511
CCL20 GeneProduct ensembl:ENSG00000115009
LGALS1 GeneProduct ensembl:ENSG00000100097
LGALS9 GeneProduct ensembl:ENSG00000168961
VEGFC GeneProduct ensembl:ENSG00000150630
MMP9 GeneProduct ensembl:ENSG00000100985
IL12B GeneProduct ensembl:ENSG00000113302
IL12A GeneProduct ensembl:ENSG00000168811
IL17A GeneProduct ensembl:ENSG00000112115
TNF GeneProduct ensembl:ENSG00000232810
CXCL1 GeneProduct ensembl:ENSG00000163739
IL5 GeneProduct ensembl:ENSG00000113525
IL6 GeneProduct ensembl:ENSG00000136244
IL2 GeneProduct ensembl:ENSG00000109471
IL13 GeneProduct ensembl:ENSG00000169194
CXCL8 GeneProduct ensembl:ENSG00000169429
TGFB1 GeneProduct ensembl:ENSG00000105329
VEGFA GeneProduct ensembl:ENSG00000112715
IL4 GeneProduct ensembl:ENSG00000113520
IFNG GeneProduct ensembl:ENSG00000111537

References

  1. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, et al. Cancer Treat Rev. 2014 May;40(4):513–22. PubMed Europe PMC Scholia
  2. The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway. Ma X, Wu D, Zhou S, Wan F, Liu H, Xu X, et al. Oncol Rep. 2016 Jan;35(1):189–96. PubMed Europe PMC Scholia
  3. Targeting tumor-associated macrophages to combat pancreatic cancer. Cui R, Yue W, Lattime EC, Stein MN, Xu Q, Tan XL. Oncotarget. 2016 Aug 2;7(31):50735–54. PubMed Europe PMC Scholia
  4. Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. Liu B, Jia Y, Ma J, Wu S, Jiang H, Cao Y, et al. Acta Biochim Biophys Sin (Shanghai). 2016 Dec;48(12):1067–74. PubMed Europe PMC Scholia
  5. Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Roy I, Boyle KA, Vonderhaar EP, Zimmerman NP, Gorse E, Mackinnon AC, et al. Lab Invest. 2017 Mar;97(3):302–17. PubMed Europe PMC Scholia
  6. Tumor microenvironment participates in metastasis of pancreatic cancer. Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Mol Cancer. 2018 Jul 30;17(1):108. PubMed Europe PMC Scholia
  7. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Masucci MT, Minopoli M, Carriero MV. Front Oncol. 2019 Nov 15;9:1146. PubMed Europe PMC Scholia
  8. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, et al. Mol Cancer. 2019 Dec 13;18(1):184. PubMed Europe PMC Scholia
  9. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Mol Cancer. 2020 Feb 15;19(1):32. PubMed Europe PMC Scholia
  10. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Zhang R, Liu Q, Peng J, Wang M, Li T, Liu J, et al. J Cancer. 2020 Feb 10;11(9):2371–81. PubMed Europe PMC Scholia
  11. T cells in pancreatic cancer stroma. Goulart MR, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM. World J Gastroenterol. 2021 Dec 14;27(46):7956–68. PubMed Europe PMC Scholia